Largest-ever drug pricing reeval to be conducted this year
By Kim, Jung-Ju | translator Alice Kang
23.01.02 06:15:11
°¡³ª´Ù¶ó
0
Systems and projects to note in the health and pharmaceutical industry in 2023
Plans for evaluating the performance of high-priced drugs and legislation of public late-night pharmacies prepared
The health and pharmaceutical industry is busy preparing various systems and policies for the new year. The reimbursement adequacy reevaluations for listed drugs that had been initiated as a pilot project on choline alfoscerate products settled as an annual policy project and are expected to start full-scale reevaluations on previously notified products.
High-priced drugs for pediatric patients will now be eligible for pharmacogenomic evaluation data exemptions (PE exemptions) and subjects for the special calculation system will also be expanded.
In addition, the 3rd Comprehensive Plan to Foster the Pharma and Bio Industry will be initiated, and the task force for the developmen
Kim, Jung-Ju(jj0831@dailypharm.com)
If you want to see the full article, please JOIN US (click)